Skip to main content

Agios Pharmaceuticals, Inc 8-K, filed Nov 5, 2026

Agios Pharmaceuticals, Inc. (AGIO)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Agios Pharmaceuticals, Inc filed this 8-K on November 5, 2026.

Agios Pharmaceuticals reported third-quarter 2026 mitapivat net revenue of $55.4 million, more than four times $12.9 million. FDA extended the sickle cell disease sNDA goal date to February 1, 2027; cash was $907.0 million at September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits